dicycloverine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 868 77-19-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dicymine
  • dicycloverine hydrochloride
  • dicycloverine
  • dicyclomine
  • dicycloverin
  • dicyclomine hydrochloride
  • dicyclomine HCl
A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.
  • Molecular weight: 309.49
  • Formula: C19H35NO2
  • CLOGP: 6.14
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -4.98
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
80 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.30 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
May 11, 1950 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 199.73 11.71 97 24207 10421 53314341
Biliary dyskinesia 106.70 11.71 42 24262 2715 53322047
Abdominal pain 101.79 11.71 301 24003 255602 53069160
Gallbladder disorder 83.57 11.71 68 24236 18097 53306665
Anxiety 71.21 11.71 224 24080 196480 53128282
Rheumatoid arthritis 60.63 11.71 34 24270 314497 53010265
Diarrhoea 58.17 11.71 484 23820 625062 52699700
Contraindicated product administered 46.91 11.71 4 24300 135625 53189137
Irritable bowel syndrome 45.87 11.71 76 24228 43556 53281206
Abdominal pain upper 45.81 11.71 173 24131 166118 53158644
Maternal exposure during pregnancy 41.39 11.71 10 24294 155629 53169133
Depression 38.28 11.71 175 24129 182877 53141885
Gallbladder injury 36.57 11.71 16 24288 1351 53323411
Glossodynia 34.56 11.71 3 24301 100288 53224474
Drug ineffective 34.45 11.71 225 24079 817020 52507742
Nausea 33.60 11.71 506 23798 755585 52569177
Cholelithiasis 33.58 11.71 64 24240 40900 53283862
Synovitis 32.77 11.71 5 24299 107888 53216874
Colitis ulcerative 32.63 11.71 44 24260 21017 53303745
Injury 29.41 11.71 69 24235 50902 53273860
Drug intolerance 28.44 11.71 31 24273 205462 53119300
Treatment failure 27.53 11.71 12 24292 128391 53196371
Gallbladder hypofunction 27.19 11.71 10 24294 536 53324226
Emotional distress 27.11 11.71 51 24253 32266 53292496
Biliary colic 27.02 11.71 18 24286 3527 53321235
Pre-existing condition improved 26.56 11.71 25 24279 8064 53316698
Pain 24.98 11.71 391 23913 588007 52736755
Joint swelling 24.82 11.71 43 24261 234595 53090167
Constipation 23.61 11.71 163 24141 198249 53126513
Abdominal distension 22.76 11.71 84 24220 79706 53245056
Therapy partial responder 22.08 11.71 20 24284 6143 53318619
Neutropenia 22.03 11.71 24 24280 159161 53165601
Flatulence 21.94 11.71 46 24258 31471 53293291
Migraine 21.56 11.71 83 24221 80334 53244428
Thrombocytopenia 21.40 11.71 19 24285 138708 53186054
Diverticulitis 21.24 11.71 49 24255 35752 53289010
Muscle spasms 21.21 11.71 119 24185 134676 53190086
Surgery 19.24 11.71 44 24260 31920 53292842
Cholecystectomy 19.15 11.71 23 24281 9792 53314970
Scleritis 18.48 11.71 14 24290 3356 53321406
Suicidal ideation 18.35 11.71 65 24239 60446 53264316
Poor peripheral circulation 18.24 11.71 14 24290 3423 53321339
Intestinal obstruction 17.78 11.71 40 24264 28701 53296061
Hypoaesthesia 17.46 11.71 112 24192 132883 53191879
Clostridium difficile infection 17.46 11.71 39 24265 27854 53296908
Pericarditis 17.38 11.71 4 24300 64402 53260360
Impaired gastric emptying 17.33 11.71 21 24283 9022 53315740
Psychological trauma 17.30 11.71 9 24295 1117 53323645
Pancytopenia 17.23 11.71 10 24294 90918 53233844
Small intestinal obstruction 16.86 11.71 29 24275 17118 53307644
Weight decreased 16.71 11.71 172 24132 234776 53089986
Palpitations 16.52 11.71 91 24213 102257 53222505
Product dose omission issue 16.46 11.71 146 24158 191474 53133288
General physical health deterioration 16.39 11.71 26 24278 146916 53177846
Drug interaction 16.06 11.71 49 24255 219280 53105482
Chest pain 15.87 11.71 144 24160 190041 53134721
Headache 15.47 11.71 336 23968 536485 52788277
Interstitial lung disease 15.12 11.71 4 24300 58618 53266144
Intestinal mucosal hypertrophy 14.67 11.71 5 24299 214 53324548
Lower respiratory tract infection 14.59 11.71 12 24292 90969 53233793
Back pain 14.58 11.71 167 24137 234080 53090682
Cholesterosis 14.50 11.71 6 24298 441 53324321
Pancreatitis 14.36 11.71 50 24254 46092 53278670
Hyponatraemia 14.34 11.71 17 24287 108590 53216172
Therapeutic product effect decreased 14.23 11.71 22 24282 125633 53199129
Colitis 13.79 11.71 46 24258 41506 53283256
Neck pain 13.74 11.71 59 24245 59957 53264805
Vulvovaginal burning sensation 13.62 11.71 9 24295 1740 53323022
Wound 13.57 11.71 13 24291 91544 53233218
Systemic lupus erythematosus 13.23 11.71 23 24281 125391 53199371
Tonsillitis fungal 13.19 11.71 3 24301 27 53324735
Arthropathy 13.13 11.71 28 24276 141425 53183337
Vulvovaginal dryness 13.11 11.71 10 24294 2422 53322340
Somnambulism 12.80 11.71 14 24290 5388 53319374
Intervertebral disc degeneration 12.54 11.71 23 24281 14275 53310487
Vulvovaginal pruritus 12.47 11.71 10 24294 2605 53322157
Rhinalgia 12.42 11.71 7 24297 1018 53323744
Diabetic neuropathy 12.37 11.71 12 24292 4015 53320747
Vision blurred 11.79 11.71 73 24231 85531 53239231

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 39.73 15.25 146 5509 364656 32143215
Irritable bowel syndrome 38.23 15.25 16 5639 3201 32504670
Abdominal pain 30.66 15.25 75 5580 149454 32358417
Colitis ulcerative 23.10 15.25 21 5634 17030 32490841
Alkalosis hypochloraemic 21.85 15.25 6 5649 330 32507541
Apathy 17.13 15.25 12 5643 6703 32501168
Nausea 16.76 15.25 104 5551 320745 32187126
Rectourethral fistula 16.07 15.25 3 5652 27 32507844

Pharmacologic Action:

SourceCodeDescription
ATC A03AA07 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, esters with tertiary amino group
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
CHEBI has role CHEBI:48876 Antimuskarinika
CHEBI has role CHEBI:50370 parasympatholytics
CHEBI has role CHEBI:53784 antispasmodics
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Irritable bowel syndrome indication 10743008 DOID:9778
Calculus in biliary tract off-label use 266474003
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.03 DRUG MATRIX CHEMBL
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.08 DRUG MATRIX CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 7.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.08 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.61 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.85 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.39 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.80 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 6.60 IUPHAR
Muscarinic acetylcholine receptor M4 GPCR Ki 9.39 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 8.77 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 8.69 DRUG MATRIX
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.55 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 4.77 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 6.33 DRUG MATRIX
SMR1-alpha2 Unclassified Ki 6.54 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.33 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.61 CHEMBL

External reference:

IDSource
4017870 VUID
N0000179550 NUI
D00717 KEGG_DRUG
67-92-5 SECONDARY_CAS_RN
4017870 VANDF
4019716 VANDF
C0012125 UMLSCUI
CHEBI:4514 CHEBI
CHEMBL1123 ChEMBL_ID
CHEMBL1200479 ChEMBL_ID
DB00804 DRUGBANK_ID
355 IUPHAR_LIGAND_ID
619 INN_ID
4KV4X8IF6V UNII
3042 PUBCHEM_CID
152021 RXNORM
158 MMSL
4587 MMSL
d00999 MMSL
001758 NDDF
004711 NDDF
372732007 SNOMEDCT_US
41493007 SNOMEDCT_US
71043005 SNOMEDCT_US
D004025 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0622 SOLUTION 10 mg ORAL ANDA 24 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 0143-1227 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-3126 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1610 CAPSULE 10 mg ORAL ANDA 27 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1620 TABLET 20 mg ORAL ANDA 27 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-7384 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-1980 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 24 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0586 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1282 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0794 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0795 TABLET 20 mg ORAL ANDA 25 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-1161 SOLUTION 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6173 INJECTION 10 mg INTRAMUSCULAR ANDA 25 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6969 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6987 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6988 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-520 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-560 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 10544-597 TABLET 20 mg ORAL ANDA 20 sections
Dicyclomine HCl HUMAN PRESCRIPTION DRUG LABEL 1 14789-010 INJECTION 10 mg INTRAMUSCULAR ANDA 25 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-077 CAPSULE 10 mg ORAL ANDA 11 sections
DICYCLOMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-324 TABLET 20 mg ORAL ANDA 8 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 17478-015 INJECTION 20 mg INTRAMUSCULAR ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0623 SOLUTION 10 mg ORAL ANDA 24 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-1161 SOLUTION 10 mg ORAL ANDA 20 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 21695-218 CAPSULE 10 mg ORAL ANDA 22 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-219 TABLET 20 mg ORAL ANDA 20 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24201-585 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 24 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 31722-963 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-163 TABLET 20 mg ORAL ANDA 26 sections